ImaRx Schedules Release of First Quarter 2008 Financi...( Live Webcast and Conference Call Sche...)
| HOME >> BIOLOGY >> TECHNOLOGY |
Live Webcast and Conference Call Scheduled for Tuesday, May 13th at 5 PM ET
TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Tuesday, May 13, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results.
The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.
Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 20, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and
commercializing therapies for vascular disorders. The Company's research
and development efforts are focused on therapies for stroke and other
vascular disorders using its proprietary microbubble technology. The
Company's commercialization efforts are currently focused on its product,
urokinase, for the treatment of acute massive pulmonary embolism.
Contacts:
The Ruth Group (Investors/Media)
Sara Ephraim/Jason Rando
646-536-7002 or 7025
'/>"/>
| SOURCE ImaRx Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
5. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
9. LifeCell Corporation Schedules Third Quarter 2007 Financial Results Conference Call; October 25, 2007 at 10:00 A.M. Eastern
10. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
11. WorldHeart Schedules Teleconference
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |